Immunitas Therapeutics launches with Series A financing

November 21, 2019Client News

Gunderson Dettmer client and single cell genomics-based drug discovery company Immunitas Therapeutics announced its $39 million Series A funding. The round was led by Leaps by Bayer and Novartis Venture Fund with participation from Evotec, M Ventures, Alexandria Venture Investments and other institutional investors.

In the announcement of the funding co-founder, director and President of Immunitas Therapeutics Lea Hachigian, Ph.D. said, “Our scientific founders are pioneers in the field of single cell sequencing and analysis. They have extensive expertise in deep computational biology, which has enabled us to discover novel therapeutic targets directly from human immunology. The data from this platform have also provided us with biomarkers for patient selection, which has potential to accelerate our development plans and provides improved chances for efficacy for individual patients.”

The Gunderson Dettmer deal team was led by Tim Ehrlich and included Jim Hauser, Stephen Damato, Joel Diamond, John Maciejewski and George Pothoulakis.